Articles Related to chemotherapeutic agents

Relapsed high-grade gliomas (HGG) respond poorly to known chemotherapeutic agents with a median survival of 3 to 6 months. Several phase II trials of Bevacizumab for salvage therapy, reported excellent response rates. The optimal dose of Bevacizumab in GBM has not been defined to date. We performed a prospective phase II trial of bevacizumab using 5 mg/kg every 2 weeks.

View complete article: PDF  |  Full-text

In recent years many progress has been achieved in the biomedical and biopharmaceutical fields particularly in drug delivery and regenerative medicine. This has been possible thanks to the increased expertise in polymers chemistry as well as the advent of innovative techniques of materials manipulation that have lead to the production of new “smart” polymeric devices with peculiar propertiesable to selectively reach almost all areas of the human body, in the case of drug delivery systems, or to reduce the chemical-physical gap between human tissues and synthetic devices, in the case of tissue engineering.

View complete article: PDF  |  Full-text  | Digital